Table 2.
Previous therapies for the study patients in the intense pulsed light (IPL)-meibomian gland expression (MGX) and MGX (control) groups.
| Therapy | No. (%) of Patients | |
|---|---|---|
| Control Group (n = 20) |
IPL-MGX Group (n = 23) |
|
| Diquafosol eyedrops | 19 (95.0) | 22 (95.7) |
| Topical steroids | 10 (50.0) | 21 (91.3) |
| Rebamipide eyedrops | 9 (45.0) | 15 (65.2) |
| Hyaluronic acid eyedrops | 8 (40.0) | 18 (78.3) |
| Punctal plugs | 8 (40.0) | 16 (69.6) |
| Preservative-free artificial tears | 8 (40.0) | 10 (43.5) |
| Omega-3 fatty acid supplementation | 3 (15.0) | 6 (26.1) |